Boeh Ing Acquires Ben Venue Labs In USA
Boehringer Ingleheim, the German chemical and pharmaceutical company,has announced that its US subsidiary Boehringer Ingleheim Corp, based in Ridgefield, Connecticut, has agreed to acquire Ohio-based Ben Venue Laboratories, an established contract developer and manufacturer of sterile pharmaceuticals.
Founded in 1938, the company is mainly a private family concern, and through its Bedford Laboratories division, which was established four years ago, Ben Venue is a leading producer of generic injectable drugs and currently markets more than 30 products. Heribert Johann, chairman of the board of managing directors at Boehringer Ingleheim, said that the acquisition of BenVenue would significantly increase the group's presence in the US market, "particularly in the area of injectables for the hospital market."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze